| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a605017 |
| Routes of administration | intravenous bolus injection |
| ATC code | |
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| ECHA InfoCard | 100.118.147 |
| Chemical and physical data | |
| Formula | C721H1142N202O204S9 |
| Molar mass | 16192.82 g·mol−1 |
  (what is this?) (verify) | |
Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF)[1] produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.[2]
- ^ Beaven AW, Shea TC (September 2007). "The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature". Supportive Cancer Therapy. 4 (4): 188–97. doi:10.3816/SCT.2007.n.014. PMID 18632516.
- ^ Kepivance entry in the public domain NCI Dictionary of Cancer Terms